相关实验视频

Updated: Jan 11, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

G-M6是一种酸三基,代表了抑制PARP1和抗癌活性的新支架

Meng Ding¹, Xu Li¹, Hongling Wang¹

¹College of Chemistry and Chemical Engineering, Cangzhou Normal University, Cangzhou 061000, Hebei, China.

Gynecologic oncology

|November 13, 2025

概括

G-M6是一种天然代谢物,有效抑制了多 (ADP-ribose) 聚合酶1 (PARP1),显示出治疗具有同源重组缺陷的癌症的前景. 这种新型的PARP1抑制剂在临床前模型中显示出强大的抗瘤活性.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
自然产品化学化学

背景情况:

聚 (ADP-ribose) 聚合酶1 (PARP1) 抑制是同源重组 (HR) 缺陷瘤的验证癌症治疗策略.
银酸代谢产物代表了新型治疗剂的潜在来源.
发现新的PARP1抑制剂对于扩大癌症治疗选择至关重要.

研究的目的:

发现和描述来自天然产品衍生来源的新型聚 (ADP-ribose) 聚合酶1 (PARP1) 抑制剂.
评估已识别的化合物G-M6.的酶活性,选择性和抗癌作用.
在临床前癌症模型中评估G-M6的体内疗效.

主要方法:

使用酶定量测试来确定G-M6对PARP1.1的IC50.
激酶选试验证实了G-M6.6的选择性.
在BRCA1缺乏的癌细胞中评估了合成致死性.
在体内有效性被评估使用老鼠异种移植模型与HR缺陷瘤.

主要成果:

G-M6表现出强烈的PARP1抑制 (IC50 = 12.38nM),与Olaparib.com相似.
与Olaparib相比,G-M6在HR缺乏的卵巢癌细胞中表现出更高的合成致命性.
口服G-M6在体内显著抑制瘤生长,在异种移植模型中表现优于Olaparib.
在HR缺陷模型中,G-M6对PARP1比其他激酶具有选择性和特异性.

结论:

G-M6是一种天然产品衍生代谢物,是一种强大的PARP1抑制剂,有效性与Olaparib.com相似.
在HR缺乏的癌细胞中,G-M6表现出合成致死性,并在体内减少瘤生长.
G-M6代表了一种有前途的化合物,用于瘤学的进一步临床前发展.

关键词:

在 G-M6 中.同类重组缺陷的同类重组缺陷卵巢癌是发生在卵巢中的癌症.在 PARP 抑制剂.合成杀伤性合成杀伤性

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...